ECS Botanics offers investors a chance to participate in a rapidly growing, certified organic medicinal cannabis business, with record FY25 harvests, 126% B2C revenue growth, and operational cash flow positivity in Q1 FY26.
ECS Botanics Holdings Ltd (ASX:ECS)
ECS
Lead Manager
Contact - Jake Grbavac
0474 484 982
jake@liquidity.com.au
Offer Price
A$0.0065
per share
Offer Size
A$1,500,000
Offer Details
Issue Price (Per Share)
A$0.0065
Discount
-30.00%
Offer Size
A$1,500,000
Shares Available
230,769,230
The Company is seeking to raise approximately A$1.5 million by issuing approximately 230.8 million new fully paid ordinary shares in the Company at A$0.0065.
Discount
18.8% discount to last price
15.6% discount to 5-day VWAP
17.6% discount to 10-day VWAP
19.1% discount to 15 Day VWAP
Options
Participants will receive 1 free attaching option for every 1 New Share allocated in the Placement, exercisable at A$0.011 with a 2.5 year expiry from date of issue.
Documents & Downloads
Company Overview
ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer operating out of Northwest Victoria, with its primary facility located alongside the Murray River. The Company employs a B2B and B2C business model, supplying pharmaceutical-grade cannabinoid products domestically and to export markets, with revenue streams from wholesale agreements and proprietary branded product lines.
ECS Botanics holds PIC/S GMP (EU-GMP equivalent) certification and is recognised as Australia's only certified organic medicinal cannabis cultivator, differentiating its products through exclusive technology and distribution agreements. Key operations focus on environmentally sustainable cultivation practices, strategic international partnerships, and compliance with major regulatory standards for pharmaceutical production.
Investment Highlights
- Record FY25 harvest of 10.6 tonnes (+60% YoY), supporting growth across domestic and export markets.
- Strong pivot into B2C, delivering $10.3m of $19.5m total revenue with continued growth expected from new FY26 product launches.
- Broad brand range and capsule innovation strengthen positioning across premium and value segments amid shifting patient and pricing dynamics.
- European footprint growing, with established German sales and Poland supply targeted in FY26.
- Certified organic cultivation and PIC/S GMP manufacturing provide a quality and regulatory advantage in global markets.
Upcoming News Flow and Catalysts
- Rolling out new high-margin products (VESIsorb pastilles, live rosin vapes) with additional organic oil SKUs planned for H1 FY26.
- Expanding into Germany, the UK, Poland, and Ireland to build a pan-European distribution network.
- Targeting organic oil certification and TGA GMP licence extension by FY26, positioning ECS as Australia’s first certified organic medicinal oil supplier.
- Securing new export and B2B agreements leveraging organic and EU-GMP credentials across Europe and the Asia-Pacific.
- Potential US regulatory easing could unlock a major new export market and improve domestic competitive dynamics.
Use of Funds
Use of Funds
1.
Product registration
2.
Purchase of inventory
3.
Sales & marketing
4.
Working capital
Disclaimer
This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of ECS Botanics Holdings Ltd. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.
Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in ECS Botanics Holdings Ltd.
